Slingshot Insights | Vrdn Overview

VRDN Overview

Upcoming Projects (VRDN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (VRDN)

A Third View: Delving into the Phase 3 THRIVE Clinical Trial topline data on Veligrotug (VRDN-001) in Patients with Active Thyroid Eye Disease
Ticker: VRDN
Executed On: Oct 17, 2024 at 08:00 AM EDT
A Second View: Delving into the Phase 3 THRIVE Clinical Trial topline data on Veligrotug (VRDN-001) in Patients with Active Thyroid Eye Disease
Ticker: VRDN
Executed On: Oct 09, 2024 at 01:00 PM EDT
Delving into the Phase 3 THRIVE Clinical Trial topline data on Veligrotug (VRDN-001) in Patients with Active Thyroid Eye Disease
Ticker: VRDN
Executed On: Sep 19, 2024 at 12:00 PM EDT
A third look discussing the clinical landscape of Thyroid Eye Disease (TED) with an updated look at Tepezza. Also reviewing the potential of Viridian Therapeutics VRDN-001, an anti-IGF-1R antibody for patients with active TED.
Tickers: VRDN, HZNP
Executed On: Sep 09, 2022 at 04:00 PM EDT
A second look discussing the clinical landscape of Thyroid Eye Disease (TED) with an updated look at Tepezza. Also reviewing the potential of Viridian Therapeutics VRDN-001, an anti-IGF-1R antibody for patients with active TED.
Tickers: VRDN, HZNP
Executed On: Sep 01, 2022 at 12:30 PM EDT
Discussing the clinical landscape of Thyroid Eye Disease (TED) with an updated look at Tepezza. Also reviewing the potential of Viridian Therapeutics VRDN-001, an anti-IGF-1R antibody for patients with active TED.
Tickers: VRDN, HZNP
Executed On: Aug 30, 2022 at 06:00 PM EDT

Upcoming & Overdue Catalysts (VRDN)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (VRDN)

Don’t see a strategic initiative related to the company you care about? Create your own!